Mavyret is a combination medication containing glecaprevir and pibrentasvir [1]. It is used to treat chronic hepatitis C virus (HCV) infection in adults [1].
What is Mavyret approved to treat?
Mavyret is approved for the treatment of chronic hepatitis C virus infection in adults. This includes genotypes 1 through 6 of the virus, without cirrhosis or with mild cirrhosis [1]. It can also be used in patients with advanced cirrhosis who are also receiving background therapy with a protease inhibitor like ritonavir [1].
How does Mavyret work?
Glecaprevir is an inhibitor of the HCV NS3/4A protease, an enzyme essential for viral replication [1]. Pibrentasvir is an inhibitor of the HCV NS5A protein, which is also crucial for viral RNA replication and assembly [1]. By targeting these two proteins, Mavyret effectively inhibits the hepatitis C virus [1].
When does Mavyret's patent protection end?
Patent protection for Mavyret is complex and involves multiple patents covering the drug and its components. Information regarding specific patent expiry dates and potential challenges can be found on resources like DrugPatentWatch.com [2].
What are the potential side effects of Mavyret?
The most common side effects reported during clinical trials for Mavyret included headache and fatigue [1]. Less common side effects can also occur [1].
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie Inc. [1].
Can Mavyret be used in patients with kidney or liver problems?
Mavyret has not been studied in patients with severe renal impairment or end-stage renal disease [1]. It is generally not recommended for patients with moderate to severe hepatic impairment due to the presence of ritonavir in some treatment regimens [1].
How is Mavyret administered?
Mavyret is taken orally as three pills once daily with food [1]. The duration of treatment varies depending on the hepatitis C genotype and whether the patient has cirrhosis [1].
What are the alternatives to Mavyret for hepatitis C treatment?
There are several other direct-acting antiviral (DAA) medications available for treating hepatitis C, including Harvoni, Epclusa, Vosevi, and Zepatier [3]. The choice of treatment depends on the specific HCV genotype, the presence of cirrhosis, and prior treatment history [3].
What is the efficacy of Mavyret?
Mavyret has demonstrated high rates of sustained virologic response (SVR), which is considered a cure for hepatitis C, in clinical trials across various genotypes [1]. SVR rates typically exceed 90% in treated patients [1].
What should patients know before starting Mavyret?
Patients should inform their healthcare provider about all their medical conditions, including liver problems, kidney problems, and if they are pregnant or breastfeeding [1]. They should also list all medications they are taking, as Mavyret can interact with other drugs [1].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209665s011lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.cdc.gov/hepatitis/hcv/hcvmed.htm